HSBC Knock-Out REGN/ DE000TT7Q2T5 /
| 08.11.2024 21:44:06 | Изменение+0.03 | Бид22:00:37 | Предложение22:00:37 | Базовый актив | Цена исполнения | Дата истечения | Тип опциона |
|---|---|---|---|---|---|---|---|
| 1.72EUR | +1.78% | - Величина цены спроса: - |
- Величина цены предложения: - |
Regeneron Pharmaceut... | 645.9095 USD | 31.12.2078 | Call |
GlobeNewswire
26.08
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Fol...
GlobeNewswire
26.08
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire
15.08
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
15.08
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimi...
GlobeNewswire
12.08
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...
GlobeNewswire
08.08
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company ...
GlobeNewswire
07.08
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
GlobeNewswire
31.07
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
GlobeNewswire
23.07
Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire
23.07
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
GlobeNewswire
16.07
Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
GlobeNewswire
10.07
Regeneron Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
GlobeNewswire
07.07
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
03.07
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...
GlobeNewswire
03.07
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
GlobeNewswire
30.06
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
28.06
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...
GlobeNewswire
27.06
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...
GlobeNewswire
26.06
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница
